Safety of Pregnancy in BRCA Mutated Breast Cancer Patients

Conditions

Breast Cancer

Keywords

Breast cancer, BRCA, Young, Survivorship

Brief summary

The present study aims at refining the understanding of the effect of pregnancy on breast cancer outcomes in the specific population of BRCA mutated patients with known history of breast cancer.

Eva Blondeaux, Arianna Meacci, M. Fragío Gil, E. Klocker, Florence Coussy et al. (45 authors)

Clinical Cancer Research2026-02-17

10.1158/1557-3265.sabcs25-pd4-07

Abstract PD12-01: Surgical management of young BRCA1/2 carriers with early onset breast cancer

S. M. Wong, Eva Blondeaux, Virginia Delucchi, F. Coussy, R. Bernstein Molho et al. (40 authors)

Clinical Cancer Research2026-02-17

10.1158/1557-3265.sabcs25-pd12-01

Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study.

Toss A, Blondeaux E, Tenedini E, Bonamici L, Graffeo R, Livraghi L, Villarreal-Garza C, Bernstein Molho R, Kwong A, Balmana J, Wildiers H, Agostinetto E, Phillips KA, Pogoda K, Renaud T, Rousset-Jablonski C, Ferrari A, Moore HCF, Peccatori FA, Paluch-Shimon S, Fruscio R, Micheri C, Wong SM, Cui W, Vernieri C, Lee MK, De Marchis L, Couch FJ, Del Mastro L, Puglisi F, Meireles PA, Kemp Z, Matikas A, Plichta J, Del Pilar Estevez-Diz M, Di Meglio A, Cichowska-Cwalinska N, Gianni C, Yerushalmi R, Sanchez-Bayona R, Mrinakova B, Matos L, Bianchini G, Caleffi M, Krivokuca A, Abdou Y, Mariño-Mariño M, Parokonnaya A, Okano M, Antone N, Saavedra C, Sonnenblick A, Duchnowska R, Pais HL, Harbeck N, Cortesi L, Delucchi V, De Angelis C, Lambertini M.

2025-11-17

10.1016/j.annonc.2025.11.004

Breastfeeding after breast cancer in young BRCA carriers.

Blondeaux E, Delucchi V, Mariamidze E, Bernstein-Molho R, Frank S, Ferrari A, Linn S, Kim HJ, Agostinetto E, Paluch-Shimon S, Cortesi L, Di Meglio A, Balmana J, Yerushalmi R, Rodriguez-Wallberg KA, Renaud T, Cui W, Moore HCF, Wong SM, Pogoda K, Lustberg M, Phillips KA, Han S, Puglisi F, Vernieri C, Bajpai J, Sonnenblick A, Rousset-Jablonski C, De Marchis L, De Giorgi U, Bianchini G, Texeira L, Duhoux FP, Villarreal-Garza C, Sini V, Fruscio R, Del Mastro L, Demeestere I, Azim HA, Peccatori FA, Partridge AH, Lambertini M.

2025-11-012 citations

10.1093/jnci/djaf177

Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers.

Perachino M, Blondeaux E, Delucchi V, Bernstein Molho R, Frank S, Paluch-Shimon S, Linn S, Di Meglio A, Peccatori F, Moore HCF, Parokonnaya A, Renaud T, Rodriguez Wallberg KA, Partridge AH, Pogoda K, Ferrari A, Wildiers H, Toss A, Rousset-Jablonski C, Kim HJ, Varela M, Cordoba O, Tanase Damian C, Marhold M, Fabi A, Graff SL, Rodriguez-Hernandez A, Okano M, Duchnowska R, Luna Pais H, Di Rocco R, Azim HA, Mariamidze E, Kourie HR, Arecco L, Carrasco E, Agostinetto E, Balmana J, Saura C, Lambertini M.

2025-08-13

10.1016/j.esmoop.2025.105513

Abstract GS1-08: Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study

Matteo Lambertini, Amir Sonnenblick, Elisa Agostinetto, Raphaëlle Bas, Hee Jeong Kim et al. (49 authors)

Clinical Cancer Research2025-06-131 citations

10.1158/1557-3265.sabcs24-gs1-08

Association between type of BRCA1/2 pathogenic/likely pathogenic variants and outcome in young patients with breast cancer: Results from an international cohort study.

Angela Toss, Eva Blondeaux, Elena Tenedini, Lia Bonamici, Rossella Graffeo et al. (20 authors)

Journal of Clinical Oncology2025-05-281 citations

10.1200/jco.2025.43.16_suppl.10509

The impact of ovarian function suppression with adjuvant endocrine therapy on survival outcomes in young germline BRCA mutation carriers with breast cancer: Secondary analysis of an international cohort study.

Paola Zagami, Yara Abdou, Virginia Delucchi, Hee Jeong Kim, Florence Coussy et al. (20 authors)

Journal of Clinical Oncology2025-05-28

10.1200/jco.2025.43.16_suppl.507

Association between chemotherapy use and clinical outcomes in young BRCA carriers with T1N0 breast cancer: Results from an international cohort study.

Filipa Lynce, Eva Blondeaux, Virginia Delucchi, Hee Jeong Kim, Rinat Bernstein‐Molho et al. (20 authors)

Journal of Clinical Oncology2025-05-28

10.1200/jco.2025.43.16_suppl.541

Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study.

Blondeaux E, Sonnenblick A, Agostinetto E, Bas R, Kim HJ, Franzoi MA, Bernstein-Molho R, Linn S, Kwong A, Pogoda K, Balmana J, Smeets A, Bajpai J, Moore HCF, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Mando P, Lee JE, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Guven DC, Lee M, Villarreal-Garza C, Hwang SE, De Marchis L, Puglisi F, Kemp Z, Meireles PA, Parokonnaya A, Werutsky G, Okano M, Azim HA, Mati K, Rosenberg S, Gelber R, Boni L, Lambertini M.

2025-05-0815 citations

10.1016/s1470-2045(25)00152-4

Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status

Matteo Lambertini, Eva Blondeaux, Loredana Maria Tomasello, Elisa Agostinetto, Anne‐Sophie Hamy et al. (39 authors)

Journal of Clinical Oncology2025-02-2411 citations

10.1200/jco-24-01334

O-087 Use and safety of assisted reproductive technology in young BRCA carriers with a pregnancy after treatment for breast cancer: results from an international cohort study

Isotta Martha Magaton, E Blandeaux, Anne‐Sophie Hamy, Sabine C. Linn, Rinat Bernstein‐Molho et al. (15 authors)

Human Reproduction2024-07-01

10.1093/humrep/deae108.093

Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study.

Matteo Lambertini, Eva Blondeaux, Loredana Maria Tomasello, Elisa Agostinetto, Anne‐Sophie Hamy et al. (20 authors)

Journal of Clinical Oncology2024-06-012 citations

10.1200/jco.2024.42.16_suppl.10503

Abstract GS02-13: Pregnancy after breast cancer in young women with germline BRCA pathogenic variants: results from an international cohort study

Matteo Lambertini, Eva Blondeaux, Elisa Agostinetto, Anne‐Sophie Hamy, Hee Jeong Kim et al. (50 authors)

Cancer Research2024-05-02

10.1158/1538-7445.sabcs23-gs02-13

266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study

M. Lambertini, Isotta Martha Magaton, Anne‐Sophie Hamy, Sabine C. Linn, Rinat Bernstein‐Molho et al. (20 authors)

ESMO Open2024-05-011 citations

10.1016/j.esmoop.2024.103325

Pregnancy After Breast Cancer in Young BRCA Carriers

Matteo Lambertini, Eva Blondeaux, Elisa Agostinetto, Anne‐Sophie Hamy, Hee Jeong Kim et al. (100 authors)

JAMA2023-12-0748 citations

10.1001/jama.2023.25463

Interventions

OTHERClinical outcomes

Clinical outcomes

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

No

Inclusion criteria

* Diagnosis of invasive breast cancer between January 2000 and December 2020; * Breast cancer diagnosis at the age of ≤ 40 years; * Known presence of germline BRCA mutation.

Exclusion criteria

* Known BRCA mutation with no diagnosis of invasive breast cancer; * Diagnosis of ovarian cancer or other malignancies with no history of invasive breast cancer; * Diagnosis of hereditary or familiar invasive breast cancer without BRCA mutation or with BRCA genes not tested; * Diagnosis of invasive breast cancer with germline BRCA variants of unknown significance.

Design outcomes

Primary

Measure	Time frame	Description
Disease-free Survival	10 years	The primary end points were the cumulative incidence of pregnancy and disease-free survival.
Cumulative Incidence of Pregnancy After Breast Cancer	10 years	The primary end points were the cumulative incidence of pregnancy and disease-free survival.

Secondary

Measure	Time frame	Description
Breast Cancer-Specific Survival	10 years	A breast cancer-specific survival event was defined as death due to breast cancer, and patients who died for reasons other than breast cancer were censored at the date of death.
Overall Survival	10 years	An overall survival event was defined as death due to any cause.

Countries

Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Canada, France, Georgia, Germany, India, Israel, Italy, Lebanon, Mexico, Netherlands, Poland, Portugal, Romania, Serbia, Slovakia, South Korea, Spain, Sweden, Switzerland, United States

Participant flow

Pre-assignment details

Subjects should meet all eligibility criteria and have available information on pregnancy status before assignment to groups

Participants by arm

Arm	Count
Pregnant Cohort Women with one or more pregnancies any time after breast cancer diagnosis Clinical outcomes: Clinical outcomes	659
Non-pregnant Cohort Women with no subsequent pregnancies after breast cancer diagnosis Clinical outcomes: Clinical outcomes	4,073
Total	4,732

Baseline characteristics

Characteristic	Pregnant Cohort	Non-pregnant Cohort	Total
Age, Continuous	30 years	35 years	35 years
Race and Ethnicity Not Collected	—	—	0 Participants
Sex: Female, Male Female	659 Participants	4073 Participants	4732 Participants
Sex: Female, Male Male	0 Participants	0 Participants	0 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	39 / 659	570 / 4,073
other Total, other adverse events	0 / 0	0 / 0
serious Total, serious adverse events	0 / 0	0 / 0

Outcome results

Primary

Cumulative Incidence of Pregnancy After Breast Cancer

The primary end points were the cumulative incidence of pregnancy and disease-free survival.

Time frame: 10 years

Arm	Measure	Value (NUMBER)
Pregnant Cohort	Cumulative Incidence of Pregnancy After Breast Cancer	22 Percentage (Cumulative incidence at 10y)

Primary

Disease-free Survival

The primary end points were the cumulative incidence of pregnancy and disease-free survival.

Time frame: 10 years

Population: A disease-free survival event was defined as the occurrence of 1 of the following invasive events: locoregional recurrence, distant metastases, new contralateral or ipsilateral invasive breast cancer, second primary malignancy, or death due to any cause.

Arm	Measure	Value (NUMBER)
Pregnant Cohort	Disease-free Survival	5.44 DFS events/100*person-year
Non-pregnant Cohort	Disease-free Survival	5.45 DFS events/100*person-year

Secondary

Breast Cancer-Specific Survival

A breast cancer-specific survival event was defined as death due to breast cancer, and patients who died for reasons other than breast cancer were censored at the date of death.

Time frame: 10 years

Population: Breast cancer-specific survival

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Pregnant Cohort	Breast Cancer-Specific Survival	35 Participants
Non-pregnant Cohort	Breast Cancer-Specific Survival	523 Participants

Secondary

Overall Survival

An overall survival event was defined as death due to any cause.

Time frame: 10 years

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Pregnant Cohort	Overall Survival	39 Participants
Non-pregnant Cohort	Overall Survival	570 Participants

Safety of Pregnancy in BRCA Mutated Breast Cancer Patients

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Pre-assignment details

Participants by arm

Baseline characteristics

Adverse events

Outcome results

Cumulative Incidence of Pregnancy After Breast Cancer

Disease-free Survival

Breast Cancer-Specific Survival

Overall Survival